Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Fuji
Baxter
AstraZeneca
Harvard Business School
Healthtrust
Johnson and Johnson
Cipla
Merck
Moodys

Generated: August 17, 2018

DrugPatentWatch Database Preview

Biocryst Company Profile

« Back to Dashboard

What is the competitive landscape for BIOCRYST, and when can generic versions of BIOCRYST drugs launch?

BIOCRYST has one approved drug.

There are three US patents protecting BIOCRYST drugs.

There are fifty-four patent family members on BIOCRYST drugs in twenty-seven countries.

Summary for Biocryst
International Patents:54
US Patents:3
Tradenames:1
Ingredients:1
NDAs:1

Drugs and US Patents for Biocryst

Glossary
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Biocryst RAPIVAB peramivir SOLUTION;INTRAVENOUS 206426-001 Dec 19, 2014 RX Yes Yes 8,778,997 ➤ Try a Free Trial ➤ Try a Free Trial
Biocryst RAPIVAB peramivir SOLUTION;INTRAVENOUS 206426-001 Dec 19, 2014 RX Yes Yes 6,503,745 ➤ Try a Free Trial Y ➤ Try a Free Trial
Biocryst RAPIVAB peramivir SOLUTION;INTRAVENOUS 206426-001 Dec 19, 2014 RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial
Biocryst RAPIVAB peramivir SOLUTION;INTRAVENOUS 206426-001 Dec 19, 2014 RX Yes Yes 6,562,861 ➤ Try a Free Trial Y ➤ Try a Free Trial
Biocryst RAPIVAB peramivir SOLUTION;INTRAVENOUS 206426-001 Dec 19, 2014 RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Non-Orange Book US Patents for Biocryst

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
9,770,427 Antiviral treatments ➤ Try a Free Trial
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Cerilliant
QuintilesIMS
Covington
Farmers Insurance
Queensland Health
Federal Trade Commission
Chinese Patent Office
Fish and Richardson
Argus Health

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2018 thinkBiotech LLC
ISSN: 2162-2639
Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions
Site Map
 
Links

Follow DrugPatentWatch: